MARKET

JNJ

JNJ

Johnson&Johnson
NYSE

Real-time Quotes | Nasdaq Last Sale

162.94
+3.56
+2.23%
After Hours: 162.95 +0.01 +0.01% 16:38 12/06 EST
OPEN
160.29
PREV CLOSE
159.38
HIGH
163.52
LOW
159.90
VOLUME
9.00M
TURNOVER
--
52 WEEK HIGH
179.92
52 WEEK LOW
148.51
MARKET CAP
428.96B
P/E (TTM)
24.35
1D
5D
1M
3M
1Y
5Y
Biden calls on Senate to pass legislation to tackle 'outrageously expensive' drug prices
President Biden this afternoon called on the Senate to pass his Build Back Better legislation, citing one of its provisions that would tackle high prescription drug prices. In an event
Seekingalpha · 48m ago
BRIEF-U.S. CDC Says Delivered 580,074,805 Doses Of Covid-19 Vaccine As Of Dec 6
reuters.com · 1h ago
UPDATE: Children Aged 5-11 Required To have At Least 1 COVID Vaccine Shot For Indoor Activities Starting Dec. 14
https://twitter.com/CBSNewYork/status/1467877940998377474
Benzinga · 6h ago
NDA for J&J's cilta-cel for multiple myeloma submitted to Japanese regulators
Legend Biotech (NASDAQ:LGND) has submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for ciltacabtagene autoleucel (cilta-cel) in multiple myeloma on behalf of Johnson & Johnson's (NYSE:JNJ)
Seekingalpha · 7h ago
Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab
Johnson & Johnson (NYSE: JNJ) 
Benzinga · 8h ago
Is Oshares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
Zacks.com · 10h ago
U.S. prepares to fast-track authorization of Omicron COVID vaccines
Omicron cases have now been identified in nearly a third of all U.S. states, prompting the FDA to speed up conversations about streamlining authorization for revamped vaccines. Agency officials have
Seekingalpha · 10h ago
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
Zacks.com · 10h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JNJ. Analyze the recent business situations of Johnson&Johnson through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

27.78%Strong Buy
38.89%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average JNJ stock price target is 187.76 with a high estimate of 215.00 and a low estimate of 169.00.
High215.00
Average187.76
Low169.00
Current 162.94
EPS
Actual
Estimate
0.651.301.952.60
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 4.03K
Institutional Holdings: 1.95B
% Owned: 74.14%
Shares Outstanding: 2.63B
TypeInstitutionsShares
Increased
1.48K
49.75M
New
96
5.33M
Decreased
1.29K
37.16M
Sold Out
93
1.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Chief Executive Officer/Director
Alex Gorsky
Vice Chairman - Management/Chief Scientific Officer
Paulus Stoffels
Vice Chairman - Management
Joaquin Duato
Chief Financial Officer/Executive Vice President
Joseph Wolk
Chief Human Resource Officer/Executive Vice President
Peter Fasolo
Executive Vice President/General Counsel
Michael Ullmann
Executive Vice President
Ashley Mcevoy
Executive Vice President
Thibaut Mongon
Executive Vice President
Michael Sneed
Executive Vice President
Jennifer Taubert
Executive Vice President
Kathryn Wengel
Lead Director/Independent Director
Anne Mulcahy
Independent Director
Mary Beckerle
Independent Director
D. Scott Davis
Independent Director
Ian Davis
Independent Director
Jennifer Doudna
Independent Director
Marillyn Hewson
Independent Director
Hubert Joly
Independent Director
Mark Mcclellan
Independent Director
Charles Prince
Independent Director
A. Eugene Washington
Independent Director
Mark Weinberger
Independent Director
Nadja West
Independent Director
Ronald Williams
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 1.06
11/22/2021
07/19/2021
Dividend USD 1.06
08/23/2021
04/20/2021
Dividend USD 1.06
05/24/2021
01/04/2021
Dividend USD 1.01
02/22/2021
10/22/2020
Dividend USD 1.01
11/23/2020
07/20/2020
Dividend USD 1.01
08/24/2020
04/14/2020
Dividend USD 1.01
05/22/2020
01/02/2020
Dividend USD 0.95
02/24/2020
10/17/2019
Dividend USD 0.95
11/25/2019
07/15/2019
Dividend USD 0.95
08/26/2019
04/25/2019
Dividend USD 0.95
05/24/2019
01/02/2019
Dividend USD 0.9
02/25/2019
10/18/2018
Dividend USD 0.9
11/26/2018
07/16/2018
Dividend USD 0.9
08/27/2018
04/26/2018
Dividend USD 0.9
05/25/2018
01/02/2018
Dividend USD 0.84
02/26/2018
10/19/2017
Dividend USD 0.84
11/27/2017
07/17/2017
Dividend USD 0.84
08/25/2017
04/27/2017
Dividend USD 0.84
05/25/2017
01/03/2017
Dividend USD 0.8
02/24/2017
About JNJ
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.

Webull offers kinds of Johnson & Johnson stock information, including NYSE:JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.